CG Oncology, Inc. Common stock (CGON)
USD 20.91
(0.87%)
USD 20.91
(0.87%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Operating Cash Flow | -45.67 Million | -29.8 Million | -13.65 Million |
| Net Income | -48.6 Million | -35.44 Million | -12.83 Million |
| Depreciation & Amortization | 17 Thousand | 15 Thousand | 10 Thousand |
| Deferred income taxes | - | - | - |
| Stock-based compensation | 1.52 Million | 676 Thousand | 1.11 Million |
| Change in working capital | 3.43 Million | 4.43 Million | -1.96 Million |
| Other non-cash items | -2.5 Million | 1.23 Million | 584 Thousand |
| Investing Cash Flow | -121.19 Million | -55.35 Million | -97 Thousand |
| Investments in PPE | - | -14 Thousand | -97 Thousand |
| Acquisitions | - | - | - |
| Investment purchases | -517.61 Million | -55.33 Million | - |
| Sales/Maturities of investments | 396.41 Million | - | - |
| Other Investing Activities | -121.19 Million | -55.33 Million | - |
| Financing Cash Flow | 86.99 Million | 119.69 Million | 15.44 Million |
| Debt repayment | -16.29 Million | - | -15.2 Million |
| Dividends payments | - | - | - |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | 103.28 Million | 119.69 Million | 245 Thousand |
| Other Financing Activities | -3.42 Million | 119.69 Million | 245 Thousand |
| Accounts receivables | - | - | - |
| Accounts payables | 2.01 Million | -18 Thousand | 578 Thousand |
| Inventory | - | - | - |
| Other working capital | 1.42 Million | 4.45 Million | -2.54 Million |
| Cash at beginning of period | 88.14 Million | 53.6 Million | 51.91 Million |
| Cash at end of period | 8.26 Million | 88.14 Million | 53.6 Million |
| Capital Expenditure | - | -14 Thousand | -97 Thousand |
| Effect of forex changes on cash | - | - | - |
| Net cash flow / Change in cash | -79.87 Million | 34.53 Million | 1.69 Million |
| Free Cash Flow | -45.67 Million | -29.81 Million | -13.75 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -18.9 Million | -16.93 Million | -48.6 Million | -16.11 Million | -12.2 Million | -11.61 Million |
| Depreciation & Amortization | 7000.00 | 4000.00 | 17 Thousand | 4000.00 | 5000.00 | 4000.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.24 Million | 1.51 Million | 1.52 Million | 778 Thousand | 394 Thousand | 177 Thousand |
| Change in working capital | 3 Million | -8.39 Million | 3.43 Million | 2.16 Million | 618 Thousand | 286 Thousand |
| Other non-cash items | -50 Thousand | -2.09 Million | -2.5 Million | -14 Thousand | 87 Thousand | 621 Thousand |
| Investing Cash Flow | -36.23 Million | -307.44 Million | -121.19 Million | 16.94 Million | -162.79 Million | 103.35 Million |
| Investments in PPE | -14 Thousand | -12 Thousand | - | - | 6000.00 | -6000.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -206.34 Million | -453.29 Million | -517.61 Million | -379.47 Million | -27.09 Million | -32.34 Million |
| Sales/Maturities of investments | 170.12 Million | 145.86 Million | 396.41 Million | - | - | 135.71 Million |
| Other Investing Activities | - | -307.43 Million | -121.19 Million | 16.94 Million | - | - |
| Financing Cash Flow | 40 Thousand | 402.65 Million | 86.99 Million | -2.88 Million | 105.87 Million | -15.22 Million |
| Debt repayment | - | -365 Thousand | -16.29 Million | -1000.00 | -67 Thousand | -15.39 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 40 Thousand | 403.02 Million | 103.28 Million | - | - | - |
| Other Financing Activities | -37 Thousand | -3.38 Million | -3.42 Million | -3.15 Million | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -168 Thousand | 1.41 Million | 2.01 Million | 1.38 Million | 590 Thousand | 49 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 3.26 Million | -9.81 Million | 1.42 Million | 780 Thousand | - | - |
| Cash at beginning of period | 77.46 Million | 8.26 Million | 88.14 Million | 10.27 Million | 78.03 Million | 693 Thousand |
| Cash at end of period | 25.15 Million | 77.46 Million | 8.26 Million | 8.26 Million | 10.27 Million | 78.03 Million |
| Capital Expenditure | -14 Thousand | -12 Thousand | - | - | 6000.00 | -6000.00 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -52.31 Million | 69.2 Million | -79.87 Million | -2 Million | -67.76 Million | 77.34 Million |
| Free Cash Flow | -16.13 Million | -26.02 Million | -45.67 Million | -16.06 Million | -10.84 Million | -10.79 Million |
SELG
ALX
ARKO
2215
MDNDF
CLG